

Sorafenib Loaded Nanoparticles by LC-MS/MS

Application #AN4600

Conditions



Column: ACE 3 C18
Dimensions: 30 x 2.1 mm
Part Number: ACE-111-0302
Mobile Phase: A: 0.1% formic acid in H₂O
B: MeCN

| Time (mins) | %B |
|-------------|----|
| 0.0 | 5 |
| 0.2 | 5 |
| 1.2 | 90 |
| 2.2 | 90 |



Flow Rate: 0.8 mL/min
Temperature: 30 °C
Detection: Waters Quattro Premier MS
ESI in positive ion mode
MRM *m/z* 465.3 → 252.2
Capillary Voltage: 3.6 kV
Cone Voltage: 45 V
Source Temperature: 100 °C
Desolvation Temperature: 400 °C
Collision Energy: 30 eV

Sorafenib is a kinase inhibitor drug, used in the treatment of thyroid carcinoma.

Sorafenib loaded PLGA nanoparticles, modified with monoclonal antibody cetuximab, were developed for targeted delivery.



Sorafenib



Mato E, Puras G, Bell O, Agirre M, Hernandez RM et al (2015) Selective Antitumoral Effect of Sorafenib Loaded PLGA Nanoparticles Conjugated with Cetuximab on Undifferentiated/Anaplastic Thyroid Carcinoma Cells. *J. Nanomed Nanotechnol* 6: 281. doi:10.4172/2157-7439.1000281

© 2015 ACT Ltd. All rights reserved. All products are available worldwide.

For more information contact your local ACE distributor or visit
www.ace-hplc.com or email: info@ace-hplc.com